HPV, Human Papillomavirus

HR HPV, HPV

ThinPrep:

THPV - HPV Only - Liquid Based Pap Collection (NO PAP)
TPAPV - Pap w/HPV (regardless of Pap result)
TPAPVG - Pap w/HPV (regardless) and reflex 16/18 if HPV+
TPAPVGN - Pap w/HPV (regardless) and reflex 16/18 if Pap – and HPV+
TPAPA - Pap w/HPV if ASCUS
TPAPACT - Pap w/HPV if ASCUS and CT
TPAPAGC - Pap w/HPV if ASCUS and GC
TPAPAGCCT - Pap w/HPV if ASCUS and GCCT

ANALHCYT - Anal cytology with HPV

This assay detects RNA from 14 high-risk types of human papillomavirus (HPV) but it does not differentiate between them. A positive result indicates the presence of HPV RNA due to one or more of the following high-risk genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. Specific genotyping for HPV types 16 and 18/45 may be requested on HPV positive samples.

Cervical/endocervical collection, vaginal collection

ThinPrep collection vial

Complete the Incyte Diagnostics requisition with the patient's demographics and relevant clinical history. Label specimen container with the patient's full first and last name, second unique identifier, and specimen source/site.

Improper or inadequate patient identification, improper fixative

Excess blood/inflammation/lubricant, scant cellularity 

Detection of high-risk HPV mRNA is dependent on the number of copies present in the specimen and may be affected by specimen collection methods, patient factors, stage of infection and the presence of interfering substances.

A negative Aptima HPV assay result does not exclude the possibility of cytologic abnormalities or of future or underlying CIN2, CIN3, or cancer.

The Aptima HPV assay should be interpreted in conjunction with other laboratory and clinical data available to the clinician.

Molecular

Aptima nucleic acid amplification

1–3 business days from receipt

Monday–Friday

Specimen is retained for 21 days from submission

87624